HCW Biologics (HCWB) Accumulated Expenses (2020 - 2025)

HCW Biologics (HCWB) has 6 years of Accumulated Expenses data on file, last reported at $1.1 million in Q4 2025.

• Quarterly Accumulated Expenses rose 13.05% year-over-year to $1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.1 million (up 13.05% YoY) and the FY2025 annual result came in at $1.1 million, up 13.05% from the prior year.
• Accumulated Expenses climbed to $1.1 million in Q4 2025, from $1.1 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $6.3 million in Q2 2024 to a low of $674296.0 in Q1 2022.
• A 5-year average of $2.0 million and a median of $1.7 million in 2022 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Accumulated Expenses jumped 397.9% — and 2025, when it tumbled 83.12%.
• Tracing HCWB's Accumulated Expenses over 5 years: stood at $2.1 million in 2021, then declined by 17.52% to $1.7 million in 2022, then soared by 49.13% to $2.6 million in 2023, then sank by 61.95% to $981940.0 in 2024, then increased by 13.05% to $1.1 million in 2025.
• The last three Accumulated Expenses figures came in at $1.1 million (Q4 2025), $1.1 million (Q3 2025), and $1.1 million (Q2 2025), per Business Quant data.